Farhad Ravandi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, talks on the Phase I COVALENT-101 study (NCT05153330), which is investigating a novel covalent menin inhibitor (BMF-219) in patients with acute myeloid leukemia (AML). Dr Ravandi also highlights other studies which have demonstrated positive outcomes with the use of menin inhibitors in patients with specific subsets of AML. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
